Literature DB >> 3301994

[Cyclosporin A eyedrops in the prevention of high-risk corneal graft rejection. II. Postoperative clinical results].

L Goichot-Bonnat, P Chemla, Y Pouliquen.   

Abstract

Twenty-four patients (25 eyes) presenting a high corneal rejection risk have been treated by an association of topical cyclosporine A (2% in castor oil) and Dexamethasone eyedrops 1% 48 h preoperatively, the posology was slowly degressive postoperatively. The mean follow-up is of 12 months. Results are 19 clear grafts among which 4 had a reversible reject reaction, 3 unreversible rejections with a totally cloudy graft (12%), 3 corneal graft oedema of nonimmunologic nature allowing a counting fingers vision. A control group of 25 patients with the same high risks of rejection treated only by topical corticosteroids followed up for the same mean time showed an obvious higher rate of failure (65%).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3301994

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  5 in total

1.  Systemic cyclosporin A in high failure risk, repeated corneal transplantation.

Authors:  S Rumelt; V Bersudsky; T Blum-Hareuveni; U Rehany
Journal:  Br J Ophthalmol       Date:  2002-09       Impact factor: 4.638

Review 2.  [Immunomodulation in penetrating keratoplasty. Current status and perspectives].

Authors:  U Pleyer
Journal:  Ophthalmologe       Date:  2003-12       Impact factor: 1.059

3.  Update on the Management of High-Risk Penetrating Keratoplasty.

Authors:  Sayena Jabbehdari; Alireza Baradaran Rafii; Ghasem Yazdanpanah; Pedram Hamrah; Edward J Holland; Ali R Djalilian
Journal:  Curr Ophthalmol Rep       Date:  2017-02-02

4.  Systemic cyclosporin A in high risk penetrating keratoplasties: a case-control study.

Authors:  A C Poon; J E Forbes; J K Dart; S Subramaniam; C Bunce; P Madison; L A Ficker; S J Tuft; D S Gartry; R J Buckley
Journal:  Br J Ophthalmol       Date:  2001-12       Impact factor: 4.638

5.  Influence of topical cyclosporine A and dissolvent on corneal epithelium permeability of fluorescein.

Authors:  J M Benítez del Castillo; A Castillo; N Toledano; S Durán; C del Aguila; M Otero; J García-Sanchez
Journal:  Doc Ophthalmol       Date:  1995       Impact factor: 2.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.